| 1.35 0.13 (10.66%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.6 | 1-year : | 1.86 |
| Resists | First : | 1.37 | Second : | 1.6 |
| Pivot price | 1.25  |
|||
| Supports | First : | 1.18 | Second : | 1.07 |
| MAs | MA(5) : | 1.24 |
MA(20) : | 1.24 |
| MA(100) : | 1.31 |
MA(250) : | 1.79 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 49 |
D(3) : | 41.2 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 3.22 | Low : | 0.91 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ENTX ] has closed above the upper band by 1.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 54.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.38 |
| Low: | 1.2 - 1.2 | 1.2 - 1.21 |
| Close: | 1.34 - 1.35 | 1.35 - 1.36 |
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Thu, 28 May 2026
Entera Bio presents clinical data on osteoporosis candidate - Investing.com UK
Thu, 28 May 2026
Experimental osteoporosis pill gets late-breaking ENDO 2026 slot - Stock Titan
Tue, 26 May 2026
ENTX - Finviz
Sun, 17 May 2026
[EFFECT] Entera Bio Ltd. SEC Filing - Stock Titan
Fri, 15 May 2026
Entera Bio (NASDAQ: ENTX) registers 19.6M shares; $14.5M possible on warrant exercises - Stock Titan
Fri, 08 May 2026
Entera Bio (ENTX) widens Q1 loss as R&D doubles and cash runway nears Q1 2027 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 23.4 (%) |
| Held by Institutions | 16 (%) |
| Shares Short | 192 (K) |
| Shares Short P.Month | 175 (K) |
| EPS | -0.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.1 % |
| Return on Equity (ttm) | -82.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -5.2 |
| PEG Ratio | 0 |
| Price to Book value | 4.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|